BASF's Evonik Ambitions Meet Wall Street Skepticism as Ag Unit Prepares for Solitude

BASF shares slip 1.5% to EUR 50.11 as JPMorgan rates the stock Underweight with a EUR 40 target, questioning a possible Evonik takeover.

BASF shareholders are being asked to weigh two very different versions of the company's future. One path leads through a multibillion-euro acquisition of Essen-based rival Evonik; the other stays the course of cost-cutting and portfolio pruning. The market, for now, is leaning toward the latter.

The Ludwigshafen chemicals giant's stock slipped 1.5% in today's session to EUR 50.11, a modest decline that nonetheless captures the unease surrounding its strategic crosscurrents. JPMorgan's Chetan Udeshi wasted little time in making his position clear, slapping an "Underweight" rating on the shares with a EUR 40 price target. His reasoning cuts to the heart of the debate: BASF could generate superior returns elsewhere with far less execution risk.

Overlap on Paper, Divergence in Practice

At first glance, a BASF-Evonik combination has surface appeal. The two companies share roughly a third of their revenue base, a figure that suggests meaningful scale advantages could be unlocked. But Udeshi points out that the overlap shrinks considerably when measured by operating profit — the metric that ultimately determines whether a deal creates or destroys value.

Together, the two groups generated approximately EUR 74.00 billion in annual sales in their most recent reporting periods. That headline number may look impressive, yet the real question is how much of it translates into earnings that can be consolidated without triggering antitrust concessions or protracted integration costs.

Udeshi acknowledges that consolidation across the European chemicals sector is a sensible route to restoring competitiveness. He simply doesn't see BASF and Evonik as the most logical pairing. A lengthy merger process would divert management attention precisely when the company can least afford distraction.

A Brutal Operating Environment

The strategic calculus unfolds against a backdrop of extraordinary pressure on German industry. Energy costs remain elevated, demand is sluggish, and Chinese competitors continue to gain ground. BASF CEO Markus Kamieth described the business climate in June as the toughest he has seen in at least 25 years.

The company's response has been aggressive cost reduction. Over the two-and-a-half years through mid-2026, BASF eliminated roughly 7,000 positions worldwide. That restructuring effort is far from complete, and adding a billion-euro takeover on top of it introduces integration risks that could derail the savings program.

Bloomberg has reported that BASF has been working with external advisers for months on the Evonik initiative. The company has filed a non-binding expression of interest for a voluntary public offer covering all Evonik shares. No agreement has been reached, and the outcome of the discussions remains entirely uncertain.

Bernstein Sees Promise, With Caveats

Not everyone on the sell side shares JPMorgan's caution. James Hooper of Bernstein Research ran the numbers on a potential combination and found the financial case attractive. Greater market presence would deliver procurement advantages and allow administrative costs to be pooled.

Even so, Bernstein trimmed its price target to EUR 61 from EUR 63 while maintaining an "Outperform" rating. Hooper conceded that the investment story becomes fundamentally more complex under the new plans. The tension between potential synergies and execution risk is not easily resolved.

The decisive variable, Hooper suggests, is return on invested capital. If the combined entity's returns fail to exceed what BASF could achieve through share buybacks or debt reduction, the transaction would erode rather than enhance shareholder confidence.

Agricultural Spinoff Marches Forward

While the Evonik question dominates headlines, BASF is simultaneously pressing ahead with the separation of its agricultural division. The transition to a standalone entity is designed to sharpen customer focus and create more transparent reporting structures.

A leadership milestone is approaching: Leta LaRush will assume the role of Senior Vice President of BASF Agricultural Solutions United States on October 1, 2026. The broader global setup for the agricultural unit is scheduled to take effect on January 1, 2027.

Should the company succeed in strengthening its core operations while swiftly capturing acquisition synergies, the earnings trajectory could shift meaningfully higher. Investors would benefit from a more diversified chemicals group with enhanced pricing power. That scenario, however, depends on flawless execution across multiple fronts.

Chart Levels and Upcoming Catalysts

From a technical standpoint, the stock's near-term direction hinges on the 200-day moving average at EUR 49.53. As long as that support holds, the broader recovery narrative remains intact. A decisive break below it would likely accelerate selling pressure toward the year's lows.

The next tangible catalysts are the US agricultural leadership transition on October 1, 2026, and the global Agricultural Solutions reorganization on January 1, 2027. Between now and then, concrete details on the financial terms of any Evonik offer will likely dictate market direction. Until those specifics emerge, shareholders face a holding pattern — one that demands patience and a clear-eyed assessment of how much execution risk they are willing to absorb.